Abstract

Accurately predicting patient outcomes is essential for optimizing treatment and improving outcomes in pediatric acute myeloid leukemia (AML). In recent years, microRNAs have emerged as a promising prognostic marker, with a growing body of evidence supporting their potential predictive value. We systematically reviewed all previous studies that have analyzed the expression of microRNAs as predictors of survival in pediatric AML and found 16 microRNAs and 4 microRNA signatures previously proposed as predictors of survival. We then used a public access cohort of 1414 pediatric AML patients from the TARGET project to develop a new predictive model using penalized lasso Cox regression based on microRNA expression. Here we propose a new score based on a 37-microRNA signature that is associated with AML and is able to predict survival more accurately than previous microRNA-based methods.

Details

Title
MiRNA expression as outcome predictor in pediatric AML: systematic evaluation of a new model
Author
Ellson, Ivan 1   VIAFID ORCID Logo  ; Martorell-Marugán, Jordi 2   VIAFID ORCID Logo  ; Carmona-Sáez, Pedro 3   VIAFID ORCID Logo  ; Ramos-Mejia, Verónica 4   VIAFID ORCID Logo 

 PTS, GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain (GRID:grid.418805.0) (ISNI:0000 0004 0500 8423) 
 PTS, GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain (GRID:grid.418805.0) (ISNI:0000 0004 0500 8423); Fundación para la Investigación Biosanitaria de Andalucía Oriental-Alejandro Otero (FIBAO), Granada, Spain (GRID:grid.418805.0) 
 PTS, GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain (GRID:grid.418805.0) (ISNI:0000 0004 0500 8423); University of Granada, Department of Statistics, Granada, Spain (GRID:grid.4489.1) (ISNI:0000 0001 2167 8994) 
 PTS, GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain (GRID:grid.418805.0) (ISNI:0000 0004 0500 8423); University of Granada, Department of Cell Biology, Faculty of Sciences, Granada, Spain (GRID:grid.4489.1) (ISNI:0000 0001 2167 8994) 
Pages
40
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20567944
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3089694824
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.